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CASE REPORT
CASE REPORT
In January 2010, a 50-year-old woman was found to 
have left cervical, left supraclavicular, and bulky mediastinal 
lymph nodes associated with an upper left lung mass mea-
suring 3 cm. The biopsy of a supraclavicular node showed a 
poorly differentiated adenocarcinoma. The patient was treated 
with six cycles of a pemetrexed-cisplatin and bevacizumab 
combination followed by a bevacizumab maintenance treat-
ment until August 2010, with partial response to treatment. At 
the time of progression, the histological and molecular char-
acteristics of the tumor were reviewed and fluorescent in situ 
hybridization analysis demonstrated an echinoderm microtu-
bule-associated protein-like 4 (EML4)-anaplastic lymphoma 
kinase (ALK) rearrangement. The patient was randomized in 
a docetaxel part of a trial comparing chemotherapy with crizo-
tinib. A partial response was achieved after 6 weeks and lasted 
for 3 months. Thereafter, the disease progressed with the 
appearance of left cervical nodes. The patient was switched 
to crizotinib treatment with a quick dramatic response. After 
6 weeks of treatment, we observed a complete disappear-
ance of cervical lymph nodes and a near-complete response 
on the computed tomography scan of the chest, with a dra-
matic improvement of quality of life (Fig. 1A and B). After 
5.5 months of treatment, the disease relapsed with the reap-
pearance of a left supraclavicular lymph node, mediastinal 
nodes, and brain metastases. Crizotinib treatment was stopped 
in May 2011. Fifteen days later, the patient was referred to the 
“emergency room” with a left-sided neurological deficit and a 
massive enlargement of cervical lymph nodes. A body com-
puted tomography scan disclosed cerebral edema and growth 
of brain metastasis associated with chest and abdominal mas-
sive progression of the tumor (Fig. 2A and B). The diagnosis 
of the disease flare was advocated and a brain radiotherapy 
followed by a new line of chemotherapy was initiated.
DISCUSSION
Acquired resistance to tyrosine kinase inhibitors (TKIs) 
may occur in patients who initially respond to TKI treatment. 
This resistance was associated with the development of a sec-
ondary T790M mutation in the endothelial growth factor recep-
tor (EGFR) setting. Currently, six different mutations within the 
ALK tyrosine kinase domain that confer resistance to multiple 
ALK inhibitors have been identified.1–5 Not every cell is resis-
tant, and if the kinase inhibitor is stopped, growth is acceler-
ated in the sensitive clone, resulting in rapid progression. This 
mechanism has been described previously in EGFR-mutant 
lung cancers that have developed acquired resistance to EGFR 
TKI, and we believe that the current clinical case suggests that 
tumor flare may also occur in EML4-ALK tumors resistant to 
crizotinib. In patients with acquired clinical resistance to EGFR 
TKI therapy, a 23% flare rate during the EGFR TKI washout 
period has been recently reported. This tumor flare was defined 
as hospitalization or death attributable to disease progression. 
Chaft et al.3 characterized the flare as association of a shorter 
time to progression on initial TKI, preceding symptoms of dis-
ease progression and presence of central nervous system and 
pleural disease. Our case corresponds to Chaft’s description of 
flare disease after crizotinib treatment cessation.
CONCLUSION
The possibility of a tumor flare should be taken into 
account in cases of EML4-ALK tumors. Despite progressive 
disease, the kinase inhibitor might be continued until a new 
treatment is initiated.
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FIGURE 1. A, Chest CT scan  
showing lung disease in remission 
after treatment by crizotinib.  
B, Abdominal CT scan at the finish 
of crizotinib treatment without any 
liver lesion (a normal CT scan—
January 12, 2011). CT, computed 
tomography.
FIGURE 2. A, Chest CT scan 
performed 15 days after stopping 
crizotinib treatment showing  
flare- up disease with dramatic  
progression of left lung tumor 
(arrow); (B), Abdominal CT scan 
showing flare-up disease with  
the appearance of three liver metas-
tasis (arrows). CT scan performed 
on June 14, 2011, 15 days after 
stopping crizotinib treatment.  
CT, computed tomography.
